Point72 Asset Management's 9.9% Stake in C4 Therapeutics

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, filed a Schedule 13G to report a 9.9% beneficial ownership in C4 Therapeutics, Inc. The ownership includes 22,647,647 shares of common stock, with 14,170,000 shares issuable upon the exercise of warrants. The warrants are subject to a 9.99% blocker, which limits the exercise of the warrants to prevent ownership from exceeding 9.99% of the outstanding common stock. The filing was made jointly by the entities and individuals, as per Rule 13d-1(k) of the Securities Exchange Act of 1934. The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer.